Release Date: 2024-06-19

Lhrh Agonist and Antagonist for Metastatic Prostate Cancer

Bekir Demirtas (Author), Ozgur Kazan (Author)

Release Date: 2024-06-19

Alcohol consumption is a major risk factor for numerous systemic diseases, affecting various organs and systems in the body. The World Health Organization (WHO) identifies alcohol consumption as a high-risk factor for diseases such as ischemic heart disease and diabetes. The impact of alcohol is influenced by both the amount and patterns of drinking, with [...]

Media Type
    Buy from

    Price may vary by retailers

    Work TypeBook Chapter
    Published inCurrent Management of Metastatic Prostate Cancer
    First Page23
    Last Page34
    DOIhttps://doi.org/10.69860/nobel.9786053359142.2
    Page Count12
    Copyright HolderNobel Tıp Kitabevleri
    Licensehttps://nobelpub.com/publish-with-us/copyright-and-licensing

    LHRH agonists and antagonists are crucial in managing metastatic prostate cancer. These agents target the hypothalamus and pituitary gland, suppressing the production of luteinizing hormone-releasing hormone (LHRH). By doing so, they reduce testosterone levels, a key driver of prostate cancer growth. LHRH agonists like leuprolide and goserelin are widely used as first-line treatments, while newer LHRH antagonists such as degarelix offer alternative options. Both classes of drugs have demonstrated efficacy in delaying disease progression, alleviating symptoms, and improving quality of life in metastatic prostate cancer patients. Treatment selection often considers factors such as patient preferences, side effect profiles, and cost-effectiveness, highlighting the importance of individualized care in optimizing outcomes for patients with metastatic prostate cancer.

    Bekir Demirtas (Author)
    MD, Istanbul Medeniyet University
    https://orcid.org/0000-0002-0410-8866
    3I graduated from Kocaeli University Faculty of Medicine in 2018 and currently serve as a urology resident. Throughout my career, I have contributed to both national and international publications in the field. Additionally, I have had the privilege of collaborating with esteemed professionals abroad and participating in various conferences. My experiences have enriched my understanding of urology and equipped me with valuable insights into global healthcare practices. I am passionate about advancing the field through research and clinical practice, striving to make meaningful contributions to patient care and scientific discourse.

    Ozgur Kazan (Author)
    MD, Istanbul Medeniyet University
    https://orcid.org/0000-0003-0202-0454
    3Huseyin Ozgur Kazan, M.D., FEBU, is a dedicated urologist specializing in urooncology, proficient in diverse surgical techniques including laparoscopic and endoscopic procedures. With a commitment to patient-centered care, he continuously enhances his expertise through ongoing professional development and clinical research. Fluent in English and German, he graduated from Ege University Faculty of Medicine and completed his residency at Istanbul Medeniyet University Faculty of Medicine Prof. Dr. Süleyman Yalçın City Hospital. His professional journey includes roles at various hospitals, including Kocaeli State Hospital and Kütahya Health Sciences University Evliya Çelebi Training and Research Hospital. Currently, he serves as a Urology Specialist at Istanbul Medeniyet University Faculty of Medicine Prof. Dr. Süleyman Yalçın City Hospital. Notably, his research, supported by TÜBİTAK, focused on the prognostic role of PI3K and JAK/STAT pathways in regulating PDL-1 expression in prostate cancer.

    • Wasim S, Park J, Nam S, Kim J. Review of Current Treatment Intensification Strategies for Prostate Cancer Patients. Cancers (Basel). 2023;15(23).

    • Oefelein MG, Feng A, Scolieri MJ, Ricchiutti D, Resnick MI. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology. 2000; 56(6):1021–4.

    • Bubley GJ. Is the flare phenomenon clinically significant? Urology 2001;58(2 SUPPL. 1):5–9.

    • Krakowsky Y, Morgentaler A. Risk of Testosterone Flare in the Era of the Saturation Model: One More Historical Myth. Eur Urol Focus. 2019 ; 5(1):81–9.

    • Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102(11):1531–8.

    • Seidenfeld J, Samson DJ, Hasselblad V, Aronson N, Albertsen PC, Bennett CL, et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med. 2000;132(7):566–77.

    • Østergren PB, Kistorp C, Fode M, Henderson J, Bennedbæk FN, Faber J, et al. Luteinizing Hormone-Releasing Hormone Agonists are Superior to Subcapsular Orchiectomy in Lowering Testosterone Levels of Men with Prostate Cancer: Results from a Randomized Clinical Trial. J Urol. 2017;197(6):1441–7.

    • Shim M, Bang WJ, Oh CY, Lee YS, Cho JS. Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: Goserelin versus triptorelin versus leuprolide. Investig Clin Urol. 2019;60(4):244.

    • Reis LO, Denardi F, Faria EF, Silva ED. Correlation Between Testosterone and PSA Kinetics in Metastatic Prostate Cancer Patients Treated With Diverse Chemical Castrations. Am J Mens Health. 2015;9(5):430–4.

    • South D, Moul JW. Utility of LHRH antagonists for advanced prostate cancer. Can J Urol. 2014;21(2 Supp 1):22-27.

    • Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int.; 2008;102(11):1531–8

    • Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102(11):1531–8.

    • Shore ND. Experience with degarelix in the treatment of prostate cancer. Ther Adv Urol. 2013;5(1):11–24.

    • Sciarra A, Fasulo A, Ciardi A, Petrangeli E, Gentilucci A, Maggi M, et al. A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists for advanced prostate cancer. Medicine. 2016;95(27).

    • Cirne F, Aghel N, Petropoulos JA, Klotz L, Lenihan DJ, Saad F, et al. The cardiovascular effects of gonadotropin-releasing hormone antagonists in men with prostate cancer. Eur Heart J Cardiovasc Pharmacother. 2022;8(3):253–62

    • Abufaraj M, Iwata T, Kimura S, Haddad A, Al-Ani H, Abusubaih L, et al. Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials. Eur Urol. 2021;79(1):44–53.

    • Shore ND, Saad F, Cookson MS, George DJ, Saltzstein DR, Tutrone R, et al. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. N Engl J Med. 2020;382(23):303–4.

    • FDA approves relugolix for advanced prostate cancer | FDA. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-relugolix-advanced-prostate-cancer

    • Orgovyx | European Medicines Agency. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/orgovyx

    • Margel D, Peer A, Ber Y, Shavit-Grievink L, Tabachnik T, Sela S, et al. Cardiovascular Morbidity in a Randomized Trial Comparing GnRH Agonist and GnRH Antagonist among Patients with Advanced Prostate Cancer and Preexisting Cardiovascular Disease. J Urol. 2019;202(6):1199–207.

    • Sari Motlagh R, Abufaraj M, Mori K, Aydh A, Rajwa P, Katayama S, et al. The Efficacy and Safety of Relugolix Compared with Degarelix in Advanced Prostate Cancer Patients: A Network Meta-analysis of Randomized Trials. Eur Urol Oncol. 2022;5(2):138–45.

    • Shore ND, Saad F, Cookson MS, George DJ, Saltzstein DR, Tutrone R, et al. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. N Engl J Med. 2020;382(23):303–4.

    • Richard PO, Fleshner NE, Bhatt JR, Hersey KM, Chahin R, Alibhai SMH. Phase II, randomised, double-blind, placebo-controlled trial of methylphenidate for reduction of fatigue levels in patients with prostate cancer receiving LHRH-agonist therapy. BJU Int. 2015;116(5):744–52.

    • Schröder FH, Collette L, De Reijke TM, Whelan P, Pavone-Macaluso M, Mattelaer J, et al. Prostate cancer treated by anti-androgens: is sexual function preserved? EORTC Genitourinary Group. European Organization for Research and Treatment of Cancer. Br J Cancer. 2000;82(2):283–90.

    • Moffat LEF. Comparison of Zoladex, diethylstilbestrol, and cyproterone acetate treatment in advanced prostate cancer. Eur Urol. 1990 ;18 Suppl 3(SUPPL. 3):26–7.

    • Schröder FH, Whelan P, De Reijke TM, Kurth KH, Pavone-Macaluso M, Mattelaer J, et al. Metastatic prostate cancer treated by Flutamide versus Cyproterone acetate: Final analysis of the “European Organization for Research and Treatment of Cancer” (EORTC) protocol 30892. Eur Urol. 2004;45(4):457–64.

    • Bessone F, Lucena M, Roma MG, Stephens C, Medina-Cáliz I, Frider B, et al. Cyproterone acetate induces a wide spectrum of acute liver damage including corticosteroid-responsive hepatitis: report of 22 cases. Liver Int. 2016;36(2):302–10.

    • Thompson IM. Flare Associated with LHRH-Agonist Therapy. Rev Urol. 2001;3(Suppl3):S10.

    • Smith MR, Goode M, Zietman AL, McGovern FJ, Lee H, Finkelstein JS. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol. 2004;22(13):2546–53.

    • Iversen P. Antiandrogen monotherapy: Indications and results. Urology. 2002 Sep;60(3 SUPPL. 1):64–71.

    • Wadhwa VK, Weston R, Mistry R, Parr NJ. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values. BJU Int. 2009;104(6):800–5.

    • Dalesio O, Van Tinteren H, Clarke M, Peto R, Schroder FH. Maximum androgen blockade in advanced prostate cancer: An overview of the randomized trials. Lancet. 2000;355(9214):1491–8.

    • Shore ND, Chowdhury S, Villers A, Klotz L, Robert Siemens D, Phung D, et al. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomized, double-blind, phase 2 study. Lancet Oncol. 2016;17(2):153–63.

    • Penson DF, Armstrong AJ, Concepcion R, Agarwal N, Olsson C, Karsh L, et al. Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial. J Clin Oncol. 2016;34(18):2098–106.

    • Klotz L, O’Callaghan C, Ding K, Toren P, Dearnaley D, Higano CS, et al. Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT. J Clin Oncol. 2015;33(10):1151–6.

    • Jin C, Fan Y, Meng Y, Shen C, Wang Y, Hu S, et al. A meta-analysis of cardiovascular events in intermittent androgen-deprivation therapy versus continuous androgen-deprivation therapy for prostate cancer patients. Prostate Cancer Prostatic Dis. 2016;19(4):333–9.

    • Tsai HT, Penson DF, Makambi KH, Lynch JH, Van Den Eeden SK, Potosky AL. Efficacy of intermittent androgen deprivation therapy vs conventional continuous androgen deprivation therapy for advanced prostate cancer: a meta-analysis. Urology. 2013;82(2):327–34

    onix_3.0::thothThoth ONIX 3.0
    onix_3.0::project_museProject MUSE ONIX 3.0
    onix_3.0::oapenOAPEN ONIX 3.0
    onix_3.0::jstorJSTOR ONIX 3.0
    onix_3.0::google_booksGoogle Books ONIX 3.0
    onix_3.0::overdriveOverDrive ONIX 3.0
    onix_2.1::ebsco_hostEBSCO Host ONIX 2.1
    csv::thothThoth CSV
    json::thothThoth JSON
    kbart::oclcOCLC KBART
    bibtex::thothThoth BibTeX
    doideposit::crossrefCrossRef DOI deposit
    onix_2.1::proquest_ebraryProQuest Ebrary ONIX 2.1
    marc21record::thothThoth MARC 21 Record
    marc21markup::thothThoth MARC 21 Markup
    marc21xml::thothThoth MARC 21 XML

    Share This Chapter!